Biondvax Pharmaceuticals W5 (BVXV_t5)

Tel Aviv
1.00
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    1.00 - 1.10

BVXV_t5 Overview

Prev. Close
1
Day's Range
1-1.1
Revenue
-
Open
1.1
52 wk Range
0-0
EPS
-
Volume
0
Market Cap
12.89B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
44,410
P/E Ratio
-
Beta
-
1-Year Change
0%
Shares Outstanding
-
Next Earnings Date
-
What is your sentiment on Biondvax Pharma W5?
or
Vote to see community's results!

Biondvax Pharmaceuticals W5 News

  • BiondVax Pharma Reports Q2 Loss of $3.7M
    • ByInvesting.com-

    BiondVax Pharmaceuticals Ltd. (BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and...

Biondvax Pharmaceuticals W5 Company Profile

Biondvax Pharmaceuticals W5 Company Profile

  • Type:Equity
  • Market:Israel
  • ISIN:IL0011304008
  • S/N:01130400

BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing and commercializing of innovative products for the prevention and treatment of infectious diseases but also for other illnesses. BiondVax Pharmaceuticals Ltd core focus is to develop of NanoAbs for treatment of COVID-19, psoriasis and asthma. Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally the Company offers manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for other research and development companies. BiondVax Pharmaceuticals Ltd operates in Israel.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary